Additional research and clinical studies should clarify remaining issues, such as the correlation between plasma prolactin level and bone mineral density in PD patients, the effects of long-term levodopa treatment on bone loss, and when and what types of medicines are appropriate for bone protection. Here, PRL is linked to Parkinson disease.